While CAR-T cell therapy research has found promising results for treating tumor cells, there are many other avenues of cell therapy research which also have significant promise. One such therapy that may prove influential in the next generation of adoptive immunotherapies is the use of cytotoxic “natural killer” (NK) cells.
NK cells have the potential to treat other types of tumors that CAR-T cells may not be able to.
Cenk Sumen, PCT’s Senior Manager of Technology & Business Development, has created an overview of the potential durability, control, manufacturing, and toxicity benefits of NK CAR cell therapy compared to existing CAR-T cell therapies.
You can download this PCT-created resource right now by filling out the form on this page!